Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNM-ZnAg in symptomatic non-hospitalized COVID-19
NCT04610138Phase 2Completed
- Sponsor
- Clene Inc.
- Start
- Jun 2021
- Primary completion
- May 2022
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cnm-znag in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Clene Inc. Primary endpoint: Time to substantial alleviation of COVID-19 symptoms at 28 days. Started Jun 2021; status: completed.
02
Drugs
cnm-znag
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04610138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04610138.